⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6147682 | 0.97 | NPC1 (0.34) | — | |
| SCHEMBL6591479 | 0.94 | — | — | |
| SCHEMBL1480946 | 0.88 | — | — | |
| SCHEMBL4827904 | 0.74 | — | — | |
| SCHEMBL5796141 | 0.72 | NPC1 (0.37) | — | |
| SCHEMBL17553227 | 0.72 | NPC1 (0.33) | — | |
| SCHEMBL16345022 | 0.72 | NPC1 (0.30) | — | |
| SCHEMBL7853296 | 0.72 | NPC1 (0.33) | — | |
| SCHEMBL16344920 | 0.72 | NPC1 (0.33) | — | |
| SCHEMBL237734 | 0.72 | CYP1A2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-08-19 | — | — | US | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112961149-A | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| EP-3180335-B1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-107074841-B | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000066588-A1 | DIRECT C-14 OXIDATION OF OPIOIDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENTOF HEALTH A ND HUMAN SERVICES (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |